2025 FDA TIDES Harvest: Five Peptide and Oligonucleotide Approvals
2025-12-01
FDA approved 46 novel drugs in 2025 including five TIDES therapeutics, underscoring the growing clinical relevance of peptide and oligonucleotide drugs.
The FDA approved 46 novel drugs in 2025, including five TIDES (peptides and oligonucleotides) therapeutics. The approved TIDES include one peptide (elamipretide), three oligonucleotides (fitusiran, donidalorsen, plozasiran), and one antibody-drug conjugate containing a peptide payload (telisotuzumab vedotin-tllv).
Key approvals include fitusiran (Qfitlia) as the first oligonucleotide therapy for antithrombin deficiency, donidalorsen as the first for hereditary angioedema, and plozasiran as the second therapy for familial chylomicronemia syndrome.
Peptides have established a strong presence in the pharmaceutical landscape with 34 FDA approvals between 2016 and 2024. The 2025 approvals further underscore the growing clinical relevance of peptide-based and ADC therapies in expanding the therapeutic landscape for complex and previously unmet medical needs.
Read Full Source Article